DK3212212T3 - Pulverformulering - Google Patents

Pulverformulering Download PDF

Info

Publication number
DK3212212T3
DK3212212T3 DK15813099.7T DK15813099T DK3212212T3 DK 3212212 T3 DK3212212 T3 DK 3212212T3 DK 15813099 T DK15813099 T DK 15813099T DK 3212212 T3 DK3212212 T3 DK 3212212T3
Authority
DK
Denmark
Prior art keywords
powder formulation
formulation
powder
Prior art date
Application number
DK15813099.7T
Other languages
English (en)
Inventor
James John Mitchell
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Monash filed Critical Univ Monash
Application granted granted Critical
Publication of DK3212212T3 publication Critical patent/DK3212212T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15813099.7T 2014-10-31 2015-10-29 Pulverformulering DK3212212T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073821P 2014-10-31 2014-10-31
US201562189252P 2015-07-07 2015-07-07
PCT/IB2015/058373 WO2016067252A1 (en) 2014-10-31 2015-10-29 Powder formulation

Publications (1)

Publication Number Publication Date
DK3212212T3 true DK3212212T3 (da) 2020-12-21

Family

ID=54884088

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15813099.7T DK3212212T3 (da) 2014-10-31 2015-10-29 Pulverformulering

Country Status (10)

Country Link
US (1) US10806770B2 (da)
EP (1) EP3212212B1 (da)
CN (1) CN107106641B (da)
AU (1) AU2015338717B2 (da)
CA (1) CA2965759C (da)
DK (1) DK3212212T3 (da)
ES (1) ES2841933T3 (da)
MX (1) MX392636B (da)
WO (1) WO2016067252A1 (da)
ZA (1) ZA201702717B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
WO2019222463A1 (en) * 2018-05-16 2019-11-21 Massachusetts Institute Of Technology Methods and apparatus for passive, proportional, valveless gas sampling and delivery

Family Cites Families (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE430885B (sv) 1980-03-24 1983-12-19 Ferring Ab Oxytocin-derivat
NL192564C (nl) 1982-10-08 1997-10-03 Glaxo Group Ltd Inrichting voor het toedienen van medicamenten aan patiënten.
EP0211595B1 (en) 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
DE3886880T2 (de) 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
EP0360340A1 (en) 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
CA2081474A1 (en) 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
EP0611567B1 (en) 1992-06-12 2002-08-28 Teijin Limited Ultrafine powder for inhalation and production thereof
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
WO1994016756A1 (en) 1993-01-29 1994-08-04 Miris Medical Corporation Intrapulmonary delivery of hormones
US6012450A (en) 1993-01-29 2000-01-11 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
CN1318104C (zh) 1994-09-21 2007-05-30 耐科塔医药公司 送料管组件
SE9404468D0 (sv) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0817655B1 (en) 1995-03-31 2004-05-19 Aradigm Corporation Intrapulmonary delivery of hematopoietic drug
KR19980703876A (ko) 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
SI0820279T1 (en) 1995-04-14 2002-12-31 Smithkline Beecham Corporation Metered dose inhaler for albuterol
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
ES2205210T3 (es) 1996-04-29 2004-05-01 Quadrant Technologies Ltd. Procedimientos de inhalacion de polvos secos.
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
AU3916997A (en) 1996-08-19 1998-03-06 Vivorx Pharmaceuticals, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
JP3020141B2 (ja) 1996-10-07 2000-03-15 株式会社富士薬品 経鼻投与用製剤
AU5806998A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
ZA9711732B (en) 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
DE69828155T2 (de) 1997-03-20 2005-12-22 Schering Corp. Herstellung von pulveragglomeraten
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
AUPO871997A0 (en) 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999016420A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
DE69813853T3 (de) 1997-09-29 2011-05-12 Novartis Ag Perforierte mikroteilchen und deren verwendung
CN1244794A (zh) 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
GB9727102D0 (en) 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
US5902844A (en) 1998-02-02 1999-05-11 Applied Analytical Industries, Inc. Spray drying of pharmaceutical formulations containing amino acid-based materials
AU750539B2 (en) 1998-03-16 2002-07-18 Novartis Ag Aerosolized active agent delivery
JP4416325B2 (ja) 1998-08-25 2010-02-17 アルカーメス，インコーポレイテッド 安定な噴霧乾燥タンパク質製剤
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
DK1283036T3 (da) 1998-11-13 2008-03-25 Jagotec Ag Törpulver til inhalation
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6453758B1 (en) 1999-06-11 2002-09-24 Msp Corporation Efficient high-productivity cascade impactors
GB9915975D0 (en) 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
EP1210069B1 (en) 1999-08-25 2004-12-29 Advanced Inhalation Research, Inc. Large porous particles obtainable by spray-drying and suitable for pulmonary administration
WO2001013891A2 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
CA2383794A1 (en) 1999-09-07 2001-03-15 Conjuchem Inc. Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
GB0003935D0 (en) 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
EP1129705A1 (en) 2000-02-17 2001-09-05 Rijksuniversiteit te Groningen Powder formulation for inhalation
CA2406206C (en) 2000-04-17 2012-03-20 Vectura Limited Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0010709D0 (en) 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001093837A2 (en) 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
PT1913939T (pt) 2000-06-27 2017-07-19 Vectura Ltd Formulações para utilização em dispositivos inalatórios
SE516555C2 (sv) 2000-08-04 2002-01-29 Microdrug Ag Elektropulver
GB0020616D0 (en) 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
SE516554C2 (sv) 2000-08-31 2002-01-29 Microdrug Ag Uppmätt elektrodos
DE10043509A1 (de) 2000-09-01 2002-03-14 Asta Medica Ag Feste Peptidzubereitungen für die Inhalation und deren Herstellung
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2002220857A1 (en) 2000-11-30 2002-06-11 Vectura Limited Particles for use in a pharmaceutical composition
PT2283817T (pt) 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
AU2211502A (en) 2000-11-30 2002-06-11 Vectura Ltd Method of making particles for use in a pharmaceutical composition
US6595368B2 (en) 2000-12-08 2003-07-22 Msp Corporation Pre-separator for inlets of cascade impactors
US6543301B2 (en) 2000-12-08 2003-04-08 Msp Corporation Impactor nozzle plate
AUPR197000A0 (en) 2000-12-08 2001-01-11 Unisearch Limited Synthesis of small particles
EP1351704B1 (en) 2000-12-21 2007-03-07 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
WO2002062317A2 (en) 2001-02-06 2002-08-15 Innovata Biomed Limited Bimodal dry powder formulation for inhalation
US6475468B2 (en) 2001-02-15 2002-11-05 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0107106D0 (en) 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
EG24184A (en) 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US20030035774A1 (en) 2001-07-18 2003-02-20 Adjei Akwete L. Salt/ion pair medicinal aerosol formulation
EP1418890B1 (en) 2001-08-16 2008-05-14 Baxter International Inc. Propellant-based microparticle formulations
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
AU2002335046A1 (en) 2001-10-19 2003-05-06 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
TW200300696A (en) 2001-11-01 2003-06-16 Inhale Therapeutic Syst Spray drying methods and related compositions
US20030166509A1 (en) 2001-11-20 2003-09-04 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery and methods of use thereof
JP4368198B2 (ja) 2001-11-20 2009-11-18 アルカーメス，インコーポレイテッド 肺送達用の改良された粒状組成物
FR2834636B1 (fr) 2002-01-15 2006-02-24 El Hassane Larhrib Procede de fabrication de particules micro-poreuses creuses, notamment destinees a etre inhalees
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003072080A1 (en) 2002-02-22 2003-09-04 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
DE60329744D1 (de) 2002-02-22 2009-12-03 Ajinomoto Kk Aminosäurepulver und verfahren zu seiner herstellung
WO2003077834A2 (en) 2002-03-15 2003-09-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2003079993A2 (en) 2002-03-20 2003-10-02 Advanced Inhalation Research, Inc. hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
JP2005530725A (ja) 2002-04-12 2005-10-13 カンピナ・ネーデルラント・ホールディング・ベスローテン・フェンノートシャップ ドライパウダー吸入製剤において使用する賦形剤
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2006513139A (ja) 2002-07-03 2006-04-20 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療薬の全身性送達のための中央部気道投与
CA2500065A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300427D0 (en) 2003-01-09 2003-02-05 Univ Strathclyde Pharmaceutical composition
US20040184995A1 (en) 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
CA2519228C (en) 2003-03-20 2014-10-14 Galephar M/F Improved dry powder inhaler system
WO2005035088A2 (en) 2003-07-18 2005-04-21 Baxter International, Inc. Method for preparing small spherical by controlled phase separation
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
DE10339197A1 (de) 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JP2007509941A (ja) 2003-10-28 2007-04-19 グラクソ　グループ　リミテッド ラクトース無水物を用いる吸入医薬製剤およびその投与方法
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
US20050191246A1 (en) 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
DE102004002926A1 (de) 2004-01-20 2005-08-18 Living Byte Software Gmbh USB-Vorrichtung
CA2554973A1 (en) 2004-02-10 2005-08-25 Advanced Inhalation Research, Inc. Particles for inhalation rapid release properties
US20050186146A1 (en) 2004-02-12 2005-08-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (sv) 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
BRPI0509736A (pt) 2004-04-09 2007-09-25 Nutricia Nv composição nutricional completa lìquida adequada para alimentar pacientes caquéticos, produto alimentìcio acondicionado, pó, e, processo para a preparação de um produto lìquido
DE102004022928A1 (de) 2004-05-10 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung
DE102004022926A1 (de) 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
SE0402345L (sv) 2004-09-24 2006-03-25 Mederio Ag Uppmätt läkemedelsdos
WO2006055950A1 (en) 2004-11-18 2006-05-26 Nektar Therapeutics Pharmaceutical dry powder formulation on the basis particles comprising multiple active agents
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1850749A2 (en) 2005-01-10 2007-11-07 Pulmatrix, Inc. Method and device for decreasing contamination
AU2006244478B2 (en) 2005-05-05 2012-09-13 Pulmatrix Inc. Ultrasonic aerosol generator
EP1906922A2 (en) 2005-05-18 2008-04-09 Pulmatrix, Inc. Formulations for alteration of biophysical properties of mucosal lining
US7694357B2 (en) 2005-07-06 2010-04-13 Joanne Alvite Safety bar for a bathtub
CA2616778A1 (en) 2005-07-27 2007-02-01 Nastech Pharmaceutical Company Inc. Tight junction modulating peptide components for enhancing mucosal delivery of therapeutic agents
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
JP4878463B2 (ja) 2005-09-13 2012-02-15 ホソカワミクロン株式会社 ペプチドホルモン封入ナノ粒子を含む医薬製剤及びその製造方法
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
AU2007208998A1 (en) 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
EP1986674A4 (en) 2006-02-13 2009-11-11 Nektar Therapeutics PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
CN101466436A (zh) 2006-04-12 2009-06-24 普马特里克斯公司 测定颗粒产生的诊断装置
FR2902007B1 (fr) 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
US8679540B2 (en) 2006-06-09 2014-03-25 Flamel Technologies Pharmaceutical formulations for the prolonged release of active principle(s), and their applications, especially therapeutic applications
DE102006030164A1 (de) 2006-06-29 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Pulver
WO2008013955A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Sustained release formulations for pulmonary delivery
FR2904219B1 (fr) 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
US20080102128A1 (en) 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
BRPI0716658A2 (pt) 2006-08-11 2015-02-10 Panacea Biotec Ltd Partículas para distribuição de ingredientes ativos, processo de fabricação e suas composições
JP5623743B2 (ja) * 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20100190706A1 (en) 2007-06-01 2010-07-29 Novo Nordisk A/S Stable Non-Aqueous Pharmaceutical Compositions
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
WO2009040020A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
EP2200587A1 (en) 2007-10-05 2010-06-30 President And Fellows of Harvard College Dry powders of cellular material
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
CN101317821B (zh) 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
EP2249809A1 (en) 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8714435B2 (en) 2008-04-30 2014-05-06 Lincoln Global, Inc. Collapsible carton
WO2009143011A1 (en) 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2161030A1 (en) 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
KR101419583B1 (ko) * 2008-10-15 2014-07-25 인타르시아 세라퓨틱스 인코포레이티드 고농축 약물 입자, 제형, 현탁액 및 이들의 용도
US20100183876A1 (en) 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
MX2011009251A (es) 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
EP2410985A2 (en) 2009-03-26 2012-02-01 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
MX2011009959A (es) 2009-03-26 2012-01-27 Pulmatrix Inc Formulaciones farmaceuticas y metodos para el tratamiento de enfermedades del tracto respiratorio.
CN102448438A (zh) 2009-03-26 2012-05-09 普马特里克斯公司 抗流行性感冒调配物及方法
AU2010229730A1 (en) 2009-03-26 2011-10-06 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
CA2759041A1 (en) 2009-04-24 2010-10-28 Schering Corporation Agglomerate formulations useful in dry powder inhalers
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2010132827A1 (en) 2009-05-15 2010-11-18 Bend Research, Inc. Low-molecular dextran for powder inhalations
US20100310660A1 (en) 2009-06-08 2010-12-09 Taipei Medical University Dry powder microparticles for pulmonary delivery
TWI463990B (zh) 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US9433588B2 (en) 2009-11-09 2016-09-06 Virginia Commonwealth Univeristy Delivery of submicrometer and nanometer aerosols to the lungs using hygroscopic excipients or dual stream nasal delivery
CN102858682B (zh) 2010-03-22 2014-07-16 株式会社Bio-Synectics 纳米颗粒制备方法
RU2585101C2 (ru) 2010-04-01 2016-05-27 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способ приготовления частиц носителя для сухих порошков для ингаляции
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp A dry powder inhaler and preparation for it
US20130203715A1 (en) 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CA2713560C (en) 2010-08-23 2019-10-29 Jangofish Holdings Inc. Process and method for producing foamable metals
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
EP2611416B1 (en) 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmaceutical composition suitable for use in a dry powder inhaler
RU2640921C2 (ru) 2010-09-29 2018-01-12 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
AU2011314007B2 (en) 2010-09-29 2017-01-19 Pulmatrix, Inc. Cationic dry powders
WO2012051426A2 (en) 2010-10-15 2012-04-19 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CN102228678A (zh) 2011-06-22 2011-11-02 深圳翰宇药业股份有限公司 一种卡贝缩宫素药物组合物及其制备方法
PL2739268T3 (pl) 2011-08-01 2019-07-31 Monash University Sposób i formulacja do inhalacji
JP6101268B2 (ja) 2011-08-26 2017-03-22 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 色素が捕捉されたゾルゲルフィルムに基づく亜硝酸塩テストストリップセンサ、及び、該ストリップセンサを調製するためのプロセス
MC200149A1 (fr) 2011-09-02 2012-09-26 Florent Saez Generateur bionique hybride universel
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
WO2013113767A1 (en) 2012-01-31 2013-08-08 Bioclin Bv Method for administration of a probiotic
WO2013128283A2 (en) 2012-02-28 2013-09-06 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
JP2015509788A (ja) 2012-02-29 2015-04-02 パルマトリックス，インコーポレイテッド 吸入に適した乾燥粉末
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
JP2015537025A (ja) 2012-11-16 2015-12-24 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 音響混合技術を使用して集塊物を作製するためのプロセス
CN103110611A (zh) 2012-12-11 2013-05-22 苏州惠仁生物科技有限公司 吸入剂及其制备方法与普鲁兰糖作为吸入剂载体的应用
KR102465025B1 (ko) * 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation

Also Published As

Publication number Publication date
CA2965759A1 (en) 2016-05-06
EP3212212A1 (en) 2017-09-06
EP3212212B1 (en) 2020-09-23
MX2017005692A (es) 2017-08-07
US10806770B2 (en) 2020-10-20
AU2015338717B2 (en) 2018-12-20
MX392636B (es) 2025-03-24
US20190125824A1 (en) 2019-05-02
ES2841933T3 (es) 2021-07-12
WO2016067252A1 (en) 2016-05-06
CA2965759C (en) 2023-12-12
AU2015338717A1 (en) 2017-05-18
CN107106641B (zh) 2021-12-21
CN107106641A (zh) 2017-08-29
ZA201702717B (en) 2019-06-26
BR112017008923A2 (pt) 2017-12-26

Similar Documents

Publication Publication Date Title
IL250363A0 (en) Stable formulation of anti-il-4r-alpha antibody
PL3769781T3 (pl) Stabilna formulacja anty-ifnar1
DK3542812T3 (da) Glycopeptidsammensætninger
GB201407934D0 (en) Formulation
DK3505209T3 (da) Pulverinhalator
HUE054245T2 (hu) Immunszupresszáns formuláció
PT3212237T (pt) Formulação de metotrexato
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
DK3173071T4 (da) Maropitantformulering
CL2016002705A1 (es) Formulación agroquímica
IL248835A0 (en) A preparation of ciritinib
DK3200827T3 (da) Sammensætninger
EP3181125C0 (en) CAPSULE FORMULATION
FR3021528B1 (fr) Formulation cosmetique
GB201402448D0 (en) Novel formulation
DK3193856T3 (da) Formulering
HUE047581T2 (hu) Készítmény
ZA201702717B (en) Powder formulation
IL251362A0 (en) formulation
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation
GB201404773D0 (en) Formulation
TH1601002304A (th) สารผสมเคลือบผง
TH1601003209A (th) องค์ประกอบเครื่องสำอางที่เป็นผง